Anavex Life Sciences Corp (AVXL)

[falconer66a]

What the FDA should want.

...but its approval [lecanemab] also indicates the FDA wants Alzheimer's drugs on the market if they have even limited promise.

Seems it could be the case.

Blarcamesine will beat lecanemab significantly on all counts. First, it will provide far greater restoration or maintenance of cognition. But without any of lecanemab's side effects. Perhaps a bit of dizziness until the body gets used to it.

Beyond all of that will be blarcamesine's ease of administration. No infusions. Just orally pop a pill. No running off to a medical facility infusion center.

If the FDA really wants a new Alzheimer's drug, blarcamesine will be the one.